Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Uday Deore"'
Autor:
Michelino De Laurentiis, Matteo Lambertini, Stephen Chia, Hope S Rugo, Katarina Petrakova, Cristian Villanueva, Sara Hurvitz, J. Thaddeus Beck, Agnes Lteif, Sina Haftchenary, Uday Deore, Jiwen Wu, Nagi El-Saghir
Publikováno v:
Cancer Research. 82:P1-18
Background: The phase 3 ML-3 trial demonstrated significant OS benefit for ribociclib (RIB) + fulvestrant (FUL) over placebo (PBO) + FUL as first- or second- line therapy in postmenopausal pts with HR+/HER2- advanced breast cancer (ABC). Prior treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb62fe36c399b79fd166cfdf9c73a00d
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-11
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-11
Publikováno v:
Communications in Computer and Information Science ISBN: 9783030937324
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e2666c5d3411524a40a1fb70dc7d3ea
https://doi.org/10.1007/978-3-030-93733-1_36
https://doi.org/10.1007/978-3-030-93733-1_36
Autor:
Arunava Chakravartty, Arnd Nusch, J. Thaddeus Beck, Juan Pablo Zarate, Seock-Ah Im, Dennis J. Slamon, Guy Jerusalem, Michelino De Laurentiis, Stephen Chia, Luis de la Cruz-Merino, Giulia Bianchi, Uday Deore, Gabe S. Sonke, Craig Wang, Peter A. Fasching, Patrick Neven, Tetiana Taran, Miguel Martin, Katarína Petráková
Publikováno v:
Journal of Clinical Oncology. 39:1001-1001
1001 Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6a6e8c02af76e15a6535838b2e550ee
https://doi.org/10.1200/jco.2021.39.15_suppl.1001
https://doi.org/10.1200/jco.2021.39.15_suppl.1001